-
公开(公告)号:US09821074B2
公开(公告)日:2017-11-21
申请号:US14208374
申请日:2014-03-13
Applicant: Spirogen Sàrl , Genentech, Inc.
Inventor: Philip Wilson Howard , John A. Flygare , Thomas Pillow , Binqing Wei
IPC: A61K47/48 , A61K31/5517 , C07D519/00 , C07D487/04
CPC classification number: A61K47/6869 , A61K31/5517 , A61K47/6803 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61P35/00 , C07D487/04 , C07D487/16 , C07D519/00
Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms; and X and X′ are independently selected from O, S and N(H).
-
公开(公告)号:US20170290920A1
公开(公告)日:2017-10-12
申请号:US15497656
申请日:2017-04-26
Applicant: MEDIMMUNE LIMITED , GENENTECH, INC.
Inventor: Paul Polakis , Andrew Polson , Susan Diane Spencer , Shang-Fan Yu , John A. Flygare , Janet L. Gunzner-Toste , Thomas H. Pillow , Philip Wilson Howard , Luke Masterson
IPC: A61K47/48 , A61K31/5517 , C07D487/16 , C07K19/00
CPC classification number: A61K31/5517 , A61K31/551 , A61K45/06 , A61K47/6809 , A61K47/6849 , A61K47/6867 , A61K47/6877 , A61K2300/00
Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.
-
公开(公告)号:US20170232113A1
公开(公告)日:2017-08-17
申请号:US15583492
申请日:2017-05-01
Applicant: Genentech, Inc.
Inventor: John A. Flygare , Thomas Pillow , Leanna Staben
CPC classification number: C07D417/14 , A61K47/6803 , A61K47/6805 , A61K47/6851 , A61K47/6889 , C07D403/12 , C07D403/14 , C07D471/02
Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
-
公开(公告)号:US11963994B2
公开(公告)日:2024-04-23
申请号:US17392724
申请日:2021-08-03
Applicant: GENENTECH, INC.
Inventor: Frederick Cohen , Lewis J. Gazzard , Vickie Hsiao-Wei Tsui , John A. Flygare
CPC classification number: A61K38/06 , A61K45/06 , C07K5/08 , C07K5/0804 , C07K5/0806 , C07K5/0812 , C07K5/0815 , A61K38/00
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I:
wherein R1, R2, R3, R4, R5 and R6 are as described herein.-
公开(公告)号:US11096982B2
公开(公告)日:2021-08-24
申请号:US16372940
申请日:2019-04-02
Applicant: GENENTECH, INC.
Inventor: Frederick Cohen , Lewis J. Gazzard , Vickie Hsiao-Wei Tsui , John A. Flygare
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
-
公开(公告)号:US20200087297A1
公开(公告)日:2020-03-19
申请号:US16697706
申请日:2019-11-27
Applicant: Genentech, Inc.
Inventor: John A. Flygare , Thomas Pillow , Leanna Staben
IPC: C07D417/14 , C07D471/02 , C07D403/12 , C07D403/14
Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
-
公开(公告)号:US20190054102A1
公开(公告)日:2019-02-21
申请号:US16178328
申请日:2018-11-01
Applicant: Genentech, Inc.
Inventor: John A. Flygare , Thomas H. Pillow
IPC: A61K31/704 , A61K47/68
Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.
-
公开(公告)号:US20180362644A1
公开(公告)日:2018-12-20
申请号:US15867195
申请日:2018-01-10
Applicant: Genentech, Inc.
Inventor: John A. Flygare , Thomas H. Pillow
IPC: C07K16/28 , A61K47/68 , C07D487/04 , C07D519/00 , C07K16/32 , C07K16/18
Abstract: A compound of formula I: wherein Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety.
-
公开(公告)号:US10124069B2
公开(公告)日:2018-11-13
申请号:US15182429
申请日:2016-06-14
Applicant: Genentech, Inc.
Inventor: Ho Huat Lee , Moana Tercel , John A. Flygare , Janet Gunzner-Toste , Thomas H. Pillow , Brian Safina , Leanna Staben , Vishal Verma , BinQing Wei , Guiling Zhao
Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
-
公开(公告)号:US09238675B2
公开(公告)日:2016-01-19
申请号:US14269739
申请日:2014-05-05
Applicant: GENENTECH, INC.
Inventor: Frederick Cohen , Lewis J. Gazzard , Vickie Hsiao-Wei Tsui , John A. Flygare
CPC classification number: A61K38/06 , A61K38/00 , A61K45/06 , C07K5/08 , C07K5/0804 , C07K5/0806 , C07K5/0812 , C07K5/0815
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
Abstract translation: 可用作治疗恶性肿瘤的治疗剂的具有通式I的IAP的新型抑制剂:其中R1,R2,R3,R4,R5和R6如本文所述。
-
-
-
-
-
-
-
-
-